In ovarian and breast cancers, IL-6-induced systemic inflammation enhances the mobilization of myeloid-derived suppressor cells which primed ɣδ T cells to produce galectin-1, thereby abolishing anti-tumor immunity (45). Here, IL6 is linked to breast cancer.